Get the Stockscreener App
56.50
1.05%
-0.60
Exelixis Inc stock is traded at $56.50, with a volume of 3.22M.
It is down -1.05% in the last 24 hours and up +7.46% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$57.10
Open:
$57.19
24h Volume:
3.22M
Relative Volume:
1.19
Market Cap:
$14.20B
Revenue:
$2.38B
Net Income/Loss:
$833.42M
P/E Ratio:
18.73
EPS:
3.0172
Net Cash Flow:
$917.69M
1W Performance:
+1.16%
1M Performance:
+7.46%
6M Performance:
+28.29%
1Y Performance:
+25.08%
1-Day Range:
$55.66
$57.27
1-Week Range:
$54.85
$57.57
52-Week Range:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
56.50 | 14.20B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - Yahoo Finance
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance
Exelixis Announces Zanzalintinib in Combinati - Moomoo
Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely (NASDAQ:EXEL) - Seeking Alpha
Exelixis, Inc. (EXEL) hit a 52-week high, can the run continue? - MSN
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In? - Yahoo Finance
Handa, Intas Face Patent Suits Over Exelixis Cancer Drug - Law360
Exelixis focuses on oncology pipeline as Nasdaq-listed biotech pursues growth - ad-hoc-news.de
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Exelixis (EXEL) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - AOL.com
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Nigeria
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says - marketscreener.com
UBS raises Exelixis stock price target to $52 on pipeline outlook - Investing.com Nigeria
UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating - marketscreener.com
EXEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $56 - GuruFocus
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target - Investing.com
Analyst recommendations: Adobe, AA, Nike, Exelixis… - marketscreener.com
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug? - Yahoo Finance
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Aftab Dana - Moomoo
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector - ChartMill
Seven Fleet Capital Management LP's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Defensive Index - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Biotechnology Leader with Robust Revenue Growth and High ROE - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to EBITDA forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Price to sales forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Enterprise value to EBITDA forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Exelixis falls as final analysis of zanzalintinib Phase 3 data disappoints - MSN
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib - MSN
Exelixis stock reaches all-time high of 53.97 USD By Investing.com - Investing.com South Africa
Exelixis stock reaches all-time high of 53.97 USD - Investing.com
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Actuals & Estimates (BMFBOVESPA:E2XE34) - TradingView
Enterprise value to revenue forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Liquidity Mapping Around (EXEL) Price Events - Stock Traders Daily
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):